Drug intelligence / Profile preview

AZD8108

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD8108 is an investigational small molecule drug that acts as an antagonist of the NMDA (N-methyl-D-aspartate) receptor, specifically targeting glutamate receptor ionotropic NMDA subunits. It was originally developed by AstraZeneca for the treatment of suicidal ideation. The drug was evaluated in a phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. As of early 2017, development by AstraZeneca was discontinued or divested to an unknown company and no further clinical development has been reported[1][2][3][4][7].

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on AZD8108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD8108.

Explore the full profile